Vitamin D3 improves the effects of low dose Der p 2 allergoid treatment in Der p 2 sensitized BALB/c mice

摘要: Airborne allergens can induce an immunological chronic disease characterized by airway hyper responsiveness and inflammation, mediated exaggerated Th2 immune response. Allergen-specific immunotherapy (AIT) is effective for treating this condition because it able to modify its natural course opposing the underlying pathogenic mechanisms determining suppression, deviation tolerance. The rational present study was investigate possibility of improving allergoid-based IT in terms efficacy safety. Recently, 1α,25-dihydroxyvitamin D3 (VD3), active metabolite vitamin D3, described be a potent inducer T regulatory cells good adjuvant AIT settings. We investigated whether co-administration VD3 could potentiate effect even when added low dose chemically-modified monomeric allergoid Der p 2 (d2-OID), Derp (d2)-sensitized BALB/c mice model. Control groups where treated with sham, alone or d2-OID only. not fully successful, as expected dose. administration associated some valuable, although limited, changes parameters lung. On contrary, adjuvated vaccine induced most prominent reduction eosinophilia cytokines concomitant increase IL-10 lung 2-specific IgG2a serum. addition conventional protocol would allow needed therefore, production costs. Moreover, beneficial immunomodulatory effects have been achieved oral which might favour management therapy patients their adherence, possibly enhancing treatment.